nach oben

Die Innere Medizin

Erschienen in:

01.02.2007 | Schwerpunkt: Metabolisches Syndrom

Das polyzystische Ovarsyndrom

Prototyp eines kardiometabolischen Syndroms

verfasst von: D. Heutling, H. Schulz, H. Randeva, C. Dodt, Prof. Dr. H. Lehnert

Erschienen in: Die Innere Medizin | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das polyzystische Ovarsyndrom (PCOS) ist eine häufige endokrine Erkrankung und betrifft Frauen im gebärfähigen Alter. Das klinische Bild ist von Zyklusstörungen, Infertilität und Hyperandrogenismus geprägt. Es besteht ein erhöhtes Risiko für die Entwicklung eines Typ-2-Diabetes. Die Mehrzahl der Frauen mit einem PCOS ist übergewichtig und weist eine Insulinresistenz auf, welche die wesentliche Ursache für das ungünstige kardiovaskuläre Risikoprofil und das gehäufte Auftreten eines metabolischen Syndroms ist.

Azziz R, Woods KS, Reyna R et al. (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89: 2745–2749CrossRefPubMed

Knochenhauer ES, Key TJ, Kahsar-Miller M et al. (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83: 3078–3082CrossRefPubMed

Achard C, Thiers J (1921) Le virillisme pilaire et son association à l‚insuffisiance glycolytique (diabète des femmes à barbe). Bull Acad Natl Med 86: 51–83

Stein I, Leventhal M. (1935) Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29: 181–191

Azziz R (2006) Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 91: 781–785CrossRefPubMed

Broekmans FJ, Knauff EA, Valkenburg O et al. (2006) PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 113: 1210–1217CrossRefPubMed

Amato P, Simpson JL(2004) The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18: 707–718CrossRefPubMed

Eagleson CA, Gingrich MB, Pastor CL et al. (2000) Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 85: 4047–4052CrossRefPubMed

Gilling-Smith C, Willis DS, Beard RW et al. (1994) Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 79: 1158–1165CrossRefPubMed

10.

Nelson VL, Legro RS, Strauss JF 3rd et al. (1999) Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 13: 946–957CrossRefPubMed

11.

Nelson VL, Qin Kn KN, Rosenfield RL et al. (2001) The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86: 5925–5933CrossRefPubMed

12.

Wood JR, Nelson VL, Ho C et al. (2003) The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem 278: 26380–26390CrossRefPubMed

13.

Ho CK, Wood JR, Stewart DR et al. (2005) Increased transcription and increased messenger ribonucleic acid (mRNA) stability contribute to increased GATA6 mRNA abundance in polycystic ovary syndrome theca cells. J Clin Endocrinol Metab 90: 6596–6602CrossRefPubMed

14.

Gilling-Smith C, Story H, Rogers V et al. (1997) Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 47: 93–99CrossRef

15.

Blank SK, McCartney CR, Marshall JC (2006) The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Human Reproduction Update 12: 351–361CrossRefPubMed

16.

Abbott DH, Dumesic DA, Franks S (2002) Developmental origin of polycystic ovary syndrome – a hypothesis. J Endocrinol 174: 1–5CrossRefPubMed

17.

Bruns CM, Baum ST, Colman RJ (2004) Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeys. J Clin Endocrinol Metab 89: 6218–6223CrossRefPubMed

18.

Dumesic DA, Schramm RD, Abbott DH (2005) Early origins of polycystic ovary syndrome. Reprod Fertil Dev 17: 349–360CrossRefPubMed

19.

Boden G (2003) Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 111: 121–124CrossRefPubMed

20.

Dunaif A, Segal KR, Shelley DR et al. (1992) Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41: 1257–1266PubMed

21.

Dunaif A, Segal KR, Futterweit W et al. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165–1174PubMed

22.

Ovesen P, Moller J, Ingerslev HJ et al. (1993) Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab 77: 1636–1640CrossRefPubMed

23.

Vrbikova J, Cibula D, Dvorakova K et al. (2004) Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89: 2942–2945CrossRefPubMed

24.

Williamson K, Gunn AJ, Johnson N et al. (2001) The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust N Z J Obstet Gynaecol 41: 202–206PubMed

25.

Dunaif A, Sorbara L, Delson R et al. (1993) Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes 42: 1462–1468PubMed

26.

Ciaraldi TP, Morales AJ, Hickman MG et al. (1997) Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab 82: 1421–1425

27.

Venkatesan AM, Dunaif A, Corbould A (2001) Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 56: 295–308CrossRefPubMed

28.

Li M, Youngren JF, Dunaif A et al. (2002) Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab 87: 4088–4093CrossRefPubMed

29.

Nestler JE, Barlascini CO, Matt DW et al. (1989) Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 68: 1027–1032PubMed

30.

Nestler JE, Jakubowicz DJ, de Vargas AF et al. (1998) Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83: 2001–2005CrossRefPubMed

31.

Zhang G, Garmey JC, Veldhuis JD (2000) Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17alpha-hydroxylase/17,20-lyase (CYP17) genes in porcine theca cells. Endocrinology 141: 2735–2742CrossRefPubMed

32.

Willis D, Mason H, Gilling-Smith C et al. (1996) Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 81: 302–309CrossRefPubMed

33.

Rice S, Christoforidis N, Gadd C et al. (2005) Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 20: 373–381CrossRefPubMed

34.

Nestler JE, Powers LP, Matt DW et al. (1991) A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72: 83–89PubMed

35.

Weiss JM, Polack S, Diedrich K et al. (2003) Effects of insulin on luteinizing hormone and prolactin secretion and calcium signaling in female rat pituitary cells. Arch Gynecol Obstet 269: 45–50CrossRefPubMed

36.

Dunaif A, Green G, Futterweit W et al. (1990) Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 70: 699–704PubMed

37.

Vrbikova J, Hill M, Dvorakova K et al. (2004) Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. Gynecol Obstet Invest 58: 36–41CrossRefPubMed

38.

Vrbikova J, Cibula D (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11: 277–291CrossRefPubMed

39.

Mohlig M, Jurgens A, Spranger J et al. (2006) The androgen receptor CAG repeat modifies the impact of testosterone on insulin resistance in women with polycystic ovary syndrome. Eur J Endocrinol 155: 127–130CrossRefPubMed

40.

Sam S, Dunaif A (2003) Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 14: 365–370CrossRefPubMed

41.

Apridonidze T, Essah PA, Iuorno MJ et al. (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 1929–1935CrossRefPubMed

42.

Glueck CJ, Papanna R, Wang P et al. (2003) Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52: 908–915CrossRefPubMed

43.

Carmina E, Napoli N, Longo RA et al. (2006) Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 154: 141–145CrossRefPubMed

44.

Ehrmann DA, Liljenquist DR, Kasza K et al. (2006) Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91: 48–53CrossRefPubMed

45.

Gaziano JM, Hennekens CH, O’Donnell CJ et al. (1997) Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 96: 2520–2525PubMed

46.

Talbott E, Clerici A, Berga SL et al. (1998) Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51: 415–422CrossRefPubMed

47.

Gambineri A, Pelusi C, Vicennati V et al. (2002) Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 26: 883–896CrossRefPubMed

48.

Dokras A, Bochner M, Hollinrake E et al. (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106: 131–137PubMed

49.

Ehrmann DA, Barnes RB, Rosenfield RL et al. (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22: 141–146PubMed

50.

Legro RS, Kunselman AR, Dodson WC et al. (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: 165–169CrossRefPubMed

51.

Gambineri A, Pelusi C, Manicardi E et al. (2004) Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 53:2353–2358PubMed

52.

Conn JJ, Jacobs HS, Conway GS (2000) The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol 52: 81–86CrossRef

53.

Yildiz BO, Yarali H, Oguz H et al. (2003) Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 2031–2036CrossRefPubMed

54.

Lo JC, Feigenbaum SL, Escobar GJ et al. (2006) Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: a population-based study. Diabetes Care 29: 1915–1917CrossRefPubMed

55.

Lee YH, Pratley RE (2005) The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 5: 70–75PubMed

56.

Bahceci M, Tuzcu A, Canoruc N et al. (2004) Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Horm Res 62: 283–287CrossRefPubMed

57.

Boulman N, Levy Y, Leiba R et al. (2004) Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89: 2160–2165CrossRefPubMed

58.

Diamanti-Kandarakis E, Paterakis T, Alexandraki K et al. (2006) Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21: 1426–1431CrossRefPubMed

59.

Diamanti-Kandarakis E, Alexandraki K, Piperi C et al. (2006) Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 36: 691–697CrossRefPubMed

60.

Kelly CC, Lyall H, Petrie JR et al. (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86: 2453–2455CrossRefPubMed

61.

Escobar-Morreale HF, Botella-Carretero JI, Villuendas G et al. (2004) Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 89: 806–811CrossRefPubMed

62.

Zhang YF, Yang YS, Hong J et al. (2006) Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 29: 419–423CrossRefPubMed

63.

Lewandowski KC, Komorowski J, O’Callaghan CJ et al. (2006) Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 91: 1173–1177CrossRefPubMed

64.

Bickerton AS, Clark N, Meeking D et al. (2005) Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 58: 151–154CrossRefPubMed

65.

Mohlig M, Spranger J, Osterhoff M et al. (2004) The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150: 525–532CrossRefPubMed

66.

Diamanti-Kandarakis E, Spina G, Kouli C et al. (2001) Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86: 4666–4673CrossRefPubMed

67.

Orio F Jr, Palomba S, Cascella T et al. (2004) Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89: 4588–4593CrossRefPubMed

68.

Nasiek M, Kos-Kudla B, Ostrowska Z et al. (2004) Plasma concentration of soluble intercellular adhesion molecule-1 in women with polycystic ovary syndrome. Gynecol Endocrinol 19: 208–215CrossRefPubMed

69.

Heutling D, Schulz H, Kleinstein J et al. (2006) Endothelial, inflammatory and endocrine markers in women with PCOS before and after metformin treatment. Exp Clin Endocrinol Diabetes 114: DOI: 10.1055/s-2006-933080

70.

Dahlgren E, Janson PO, Johansson S et al. (1994) Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 61: 455–460PubMed

71.

Atiomo WU, Fox R, Condon JE et al. (2000) Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol 52: 487–492CrossRef

72.

Vryonidou A, Papatheodorou A, Tavridou A et al. (2005) Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 2740–2746CrossRefPubMed

73.

Lakhani K, Hardiman P, Seifalian AM (2004) Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 175: 353–359CrossRefPubMed

74.

Carmina E, Orio F, Palomba S et al. (2006) Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 119: 356.e1–6CrossRef

75.

Vural B, Caliskan E, Turkoz E et al. (2005) Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 20: 2409–2413CrossRefPubMed

76.

Mather KJ, Verma S, Corenblum B et al. (2000) Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 85: 1851–1856CrossRefPubMed

77.

Talbott EO, Guzick DS, Sutton-Tyrrell K et al. (2000) Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20: 2414–2421PubMed

78.

Alexandraki K, Protogerou AD, Papaioannou TG et al. (2006) Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. Hormones 5: 126–136PubMed

79.

Dagre A, Lekakis J, Mihas C et al. (2006) Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome. Eur J Endocrinol 154: 883–890CrossRefPubMed

80.

Bernini GP, Sgro‘ M, Moretti A et al. (1999) Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab 84: 2008–2012CrossRefPubMed

81.

Meyer C, McGrath BP, Cameron J et al. (2005) Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 90: 4630–4635CrossRefPubMed

82.

Talbott EO, Zborowski JV, Rager JR et al. (2004) Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89: 5454–5461CrossRefPubMed

83.

Dahlgren E, Janson PO, Johansson S et al. (1992) Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71: 599–604PubMed

84.

Pierpoint T, McKeigue PM, Isaacs AJ et al. (1998) Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51: 581–586CrossRefPubMed

85.

Wild S, Pierpoint T, Jacobs H et al. (2000) Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil 3: 101–105

86.

Wild S, Pierpoint T, McKeigue P et al. (2000) Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 52: 595–600CrossRef

87.

Duleba AJ, Banaszewska B, Spaczynski RZ et al. (2003) Success of laparoscopic ovarian wedge resection is related to obesity, lipid profile, and insulin levels. Fertil Steril 79: 1008–1014CrossRefPubMed

88.

Witchel SF (2006) Puberty and polycystic ovary syndrome. Mol Cell Endocrinol 254–255: 146–153

89.

Reinehr T (2005) Clinical presentation of type 2 diabetes mellitus in children and adolescents. Int J Obes 29 (Suppl 2):105–110CrossRef

90.

Vrbikova J, Cibula D (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11: 277–291CrossRefPubMed

91.

Legro RS, Castracane VD, Kauffman RP et al. (2004) Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 59: 141–154CrossRefPubMed

92.

Legro RS (2001) Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am 28: 99–109CrossRefPubMed

93.

Kiddy DS, Hamilton-Fairley D, Seppala M et al. (1989) Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol 31: 757–763

94.

Kiddy DS, Hamilton-Fairley D, Bush A et al. (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 36: 105–111

95.

Kocak M, Caliskan E, Simsir C et al. (2002) Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 77: 101–106CrossRefPubMed

96.

Nestler JE, Jakubowicz DJ, Evans WS et al. (1998) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338: 1876–1880CrossRefPubMed

97.

Pasquali R, Gambineri A, Biscotti D et al. (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85: 2767–2774CrossRefPubMed

98.

Glueck CJ, Moreira A, Goldenberg N et al. (2003) Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 18: 1618–1625CrossRefPubMed

99.

Baillargeon JP, Jakubowicz DJ, Iuorno MJ et al. (2004) Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82: 893–902CrossRefPubMed

100.

Stas S, Appesh L, Sowers J (2006) Metabolic safety of antihypertensive drugs: myth versus reality. Curr Hypertens Rep 8: 403–408PubMed

101.

Dusing R, Lehnert H (2004) Diabetogenic effect of antihypertensive treatment: primum nil nocere. Nephrol Dial Transplant 19: 531–534CrossRefPubMed

102.

Mansfield R, Galea R, Brincat M et al. (2003) Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 79: 956–962CrossRefPubMed

103.

Seto-Young D, Paliou M, Schlosser J et al. (2005) Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 90: 6099–6105CrossRefPubMed

Titel: Das polyzystische Ovarsyndrom
Prototyp eines kardiometabolischen Syndroms
verfasst von: D. Heutling
H. Schulz
H. Randeva
C. Dodt
Prof. Dr. H. Lehnert
Publikationsdatum: 01.02.2007
Verlag: Springer-Verlag
Erschienen in: Die Innere Medizin / Ausgabe 2/2007
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-006-1776-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Das polyzystische Ovarsyndrom

Prototyp eines kardiometabolischen Syndroms

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Therapie mit Entecavir bei chronischer Hepatitis B

Mitteilungen der DGIM 02/2007

Kongresse des BDI 02/07

Mitteilungen der Akademie 02/07

Geschichte und Definition(en) des metabolischen Syndroms

Kongresse des BDI 02/2007

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin